AR069224A1 - Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico - Google Patents

Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico

Info

Publication number
AR069224A1
AR069224A1 ARP080104877A ARP080104877A AR069224A1 AR 069224 A1 AR069224 A1 AR 069224A1 AR P080104877 A ARP080104877 A AR P080104877A AR P080104877 A ARP080104877 A AR P080104877A AR 069224 A1 AR069224 A1 AR 069224A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
cell
complex
composition
cyclodextrine
Prior art date
Application number
ARP080104877A
Other languages
English (en)
Inventor
Yuichi Tozuka
Hidekazu Toyobuku
Yasuyuki Hira
Original Assignee
Otsuka Pharma Co Ltd
Takeuchi Hirofumi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Takeuchi Hirofumi filed Critical Otsuka Pharma Co Ltd
Publication of AR069224A1 publication Critical patent/AR069224A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Complejo de ácido nucleico con baja toxicidad y alto nivel de seguridad que puede mantener persistentemente un ácido nucleico, como por ejemplo ARNip (ARN interferentes pequenos) o similares, en una célula; y una composicion para el suministro de ácido nucleico que puede suministrar de un modo eficiente el complejo de ácido nucleico a una célula. Es posible obtener dicho complejo utilizando un ácido nucleico a ser introducido en una célula y una ciclodextrina altamente ramificada. Además, cuando se usa un portador que comprende: (A) una diacilfosfatidilcolina, (B) colesterol y/o un derivado del mismo y (C) una amina primaria alifática, como portador para el suministro de ácido nucleico para introducir el complejo de ácido nucleico a una célula, pueden mejorarse todavía más la seguridad, la eficiencia de suministro intracelular y la persistencia del ácido nucleico en la célula.
ARP080104877A 2007-11-08 2008-11-07 Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico AR069224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08

Publications (1)

Publication Number Publication Date
AR069224A1 true AR069224A1 (es) 2010-01-06

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104877A AR069224A1 (es) 2007-11-08 2008-11-07 Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico

Country Status (28)

Country Link
US (1) US8338584B2 (es)
EP (1) EP2217208B1 (es)
JP (1) JP5340282B2 (es)
KR (1) KR101567108B1 (es)
CN (1) CN101854918B (es)
AR (1) AR069224A1 (es)
AT (1) ATE522201T1 (es)
AU (1) AU2008325504B2 (es)
BR (1) BRPI0819187A2 (es)
CA (1) CA2704236C (es)
CO (1) CO6280469A2 (es)
CY (1) CY1112029T1 (es)
DK (1) DK2217208T3 (es)
ES (1) ES2369869T3 (es)
HK (1) HK1142278A1 (es)
HR (1) HRP20110698T1 (es)
IL (1) IL205237A0 (es)
MX (1) MX2010005094A (es)
MY (1) MY149917A (es)
NZ (1) NZ584841A (es)
PL (1) PL2217208T3 (es)
PT (1) PT2217208E (es)
RU (1) RU2465009C2 (es)
SI (1) SI2217208T1 (es)
TW (1) TWI426922B (es)
UA (1) UA97559C2 (es)
WO (1) WO2009061003A2 (es)
ZA (1) ZA201002845B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
CN103282503B (zh) 2010-12-29 2015-12-02 弗·哈夫曼-拉罗切有限公司 用于细胞内递送核酸的小分子缀合物
SI2825565T1 (sl) * 2012-03-15 2019-08-30 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Kationski polimeri na osnovi glikogena
WO2019131727A1 (ja) * 2017-12-27 2019-07-04 コニカミノルタ株式会社 医薬の評価方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) * 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) * 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
CA2465860A1 (en) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
WO2004042002A2 (en) * 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
HK1142278A1 (en) 2010-12-03
RU2465009C2 (ru) 2012-10-27
US8338584B2 (en) 2012-12-25
CA2704236A1 (en) 2009-05-14
US20100305190A1 (en) 2010-12-02
WO2009061003A2 (en) 2009-05-14
CN101854918A (zh) 2010-10-06
CA2704236C (en) 2015-09-15
PT2217208E (pt) 2011-11-08
RU2010123168A (ru) 2011-12-20
ES2369869T3 (es) 2011-12-07
EP2217208B1 (en) 2011-08-31
TWI426922B (zh) 2014-02-21
TW200927175A (en) 2009-07-01
AU2008325504A1 (en) 2009-05-14
PL2217208T3 (pl) 2012-01-31
KR20100092007A (ko) 2010-08-19
JP2011504457A (ja) 2011-02-10
WO2009061003A3 (en) 2010-05-27
MY149917A (en) 2013-10-31
MX2010005094A (es) 2010-05-27
ATE522201T1 (de) 2011-09-15
KR101567108B1 (ko) 2015-11-06
CN101854918B (zh) 2012-11-28
AU2008325504B2 (en) 2013-03-07
ZA201002845B (en) 2011-07-27
HRP20110698T1 (hr) 2011-10-31
DK2217208T3 (da) 2011-10-10
BRPI0819187A2 (pt) 2015-05-05
CO6280469A2 (es) 2011-05-20
JP5340282B2 (ja) 2013-11-13
CY1112029T1 (el) 2015-11-04
UA97559C2 (uk) 2012-02-27
NZ584841A (en) 2011-12-22
EP2217208A2 (en) 2010-08-18
SI2217208T1 (sl) 2011-11-30
IL205237A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
DOP2022000152A (es) Vacunas de arn contra el coronavirus
WO2022067130A3 (en) Prime editing guide rnas, compositions thereof, and methods of using the same
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
AR069224A1 (es) Complejo de acido nucleico y ciclodextrina altamente ramificada y composicion para el suministro de acido nucleico
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
MX364707B (es) Conjugados de proteina-agente activo y método para su preparación.
AR075445A1 (es) Soluciones amino alcoholicas, tamponadas de triamida n-(n-butil) tiofosforica (nbpt) y fertilizantes de urea para usar dichas soluciones como inhibidores de ureasa
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
PE20120115A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
BRPI0803065A2 (pt) processo para a produção de polióis
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
AR057553A1 (es) Composicion portadora para el suministro de un acido nucleico
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
BR112014013906A8 (pt) ésteres de fosfato aromáticos como componentes de formulação agroquímica
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
CL2008003820A1 (es) Metodo para producir el virus de estomatitis vesicular atenuado (vsv) en un cultivo celular que comprende introducir en un vector el gen vsv g optimizado; composicion inmunogenica que comprende el vsv atenuado; kit para producir el vsv.
CL2021001708A1 (es) Métodos para formar poliplejos
AR083453A1 (es) Composiciones y metodos para la inhibicion de la expresion de los genes rrm2
AR075688A1 (es) Composiciones y metodos para inhibir la expresion de los genes ptp 1b
AR076683A1 (es) Composiciones y metodos para inhibir la expresion de genes del receptor glucocorticoide (gcr)
AR080123A1 (es) Composiciones y metodos para la inhibicion de la expresion de los genes de la quinasa 2-kappa b (ikk2)

Legal Events

Date Code Title Description
FB Suspension of granting procedure